Revolution Medicines Nearly 140% Rally — Is It Still a Buy?
Revolution Medicines has surged in 2026, with revolution medicines nearly 140% year-to-date gains drawing investor at...
A yearly strategy formalizes harvest windows, helping you optimize tax outcomes while staying invested in index funds.
22,166 articlesRevolution Medicines has surged in 2026, with revolution medicines nearly 140% year-to-date gains drawing investor at...
A surprise rally in Kingsoft Cloud Holdings stock grabbed attention as analysts spotlight AI-driven growth. This arti...
A disciplined investment approach blends steady dividend payers with selective high-yield assets to produce durable i...
As crude prices rise, Occidental Petroleum trims its 2026 capital spending. This deep dive explains what the move mea...
A mid-size fund reduced its TriMas stake by about $5 million after a strong run, but didn’t exit the position entirel...
A large insider stake in Veris Residential stock signals conviction from an established manager. This article explain...
Structure Therapeutics stock has surged after a major hedge fund increased its stake. This article breaks down what s...
A major manager disclosed a sizable stake reduction in BXP, prompting questions about the outlook for Class A office ...
BitGo is lining up a $2 billion IPO and seeking an OCC national bank charter, while facing competition from Morgan St...
Investors chase the next big AI champion. This piece breaks down how a single AI stock could grow into a trillion-dol...
In a market fixated on the giants, Rezolve AI is flying under the radar as it grows ARR and eyes profitability in the...
PayPal’s plunging stock drags down YieldMax’s PYPY, with weekly distributions shrinking as Q4 2025 missed expectation...